Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Defibrillators are devices that helps to restore a normal heartbeat by delivering an electric pulse or shock to the heart. They are used to prevent or correct an arrhythmia, a heartbeat that is uneven or that is too slow or too fast. Defibrillators also helps to restore the heart’s beating if the heart suddenly stops. Different types of defibrillators are available which work in different ways. Automated external defibrillators (AEDs), which are in many public spaces, were developed to save the lives of people experiencing sudden cardiac arrest. Whereas, defibrillators can prevent sudden death among people who have a high risk of a life-threatening arrhythmia.
The defibrillators Market is mainly driven by increasing prevalence of lifestyle diseases, such as cardiac disorders, globally. Moreover factors such as technological advancements in defibrillators, increasing focus on providing public-access defibrillators, and growing number of training & awareness programs on defibrillators are propelling the growth of this market. Further, the rising demand for handling cardiovascular conditions is leading to innovation in implantable devices as well as external defibrillators. The capability of defibrillators to rectify conditions associated with cardiac, including ventricular tachycardia, ventricular fibrillation, and cardiac arrhythmias will further propel the market growth.
The report analyses the Defibrillators Market based on product end user and geography.
The defibrillator are available as implantable cardioverter defibrillators (ICD) and external defibrillators. Implantable cardioverter defibrillators consists of transvenous implantable cardioverter defibrillators and subcutaneous implantable cardioverter defibrillators. transvenous implantable cardioverter defibrillators are accessible as biventricular icds/cardiac resynchronization therapy defibrillators, dual-chamber ICDS, single-chamber ICDS. External defibrillators consists of automated external defibrillators, manual external defibrillators and wearable cardioverter defibrillators.
Implantable cardioverter Defibrillators are used for treatment as well as for continuous monitoring for arrhythmias as well. The scope of these devices has increased due to the integration of other technologies, such as pacemakers, with defibrillators. Whereas, external defibrillators mainly for resuscitation purposes in cases of SCA. They are also used to stabilize patients until they reach the hospital or medical help arrives. These are designed in a way such that they can be used by both the life-support trained personnel and laypersons. The recommendation for the usage of external defibrillators at public places has rapidly increased the adoption rate in the developed economies.
The major end users of the defibrillators are hospitals, clinics, and cardiac centers, pre-hospital care settings, public access markets, alternate care facilities, and home care settings. The change in policies by governments of developed countries, making it mandatory for certain arenas and institutions to store & maintain automatic external defibrillators coupled with increase in awareness and training programs, are the factors that are leading to more adaption of these systems in public access markets.
The global study conducted defibrillators vertical to estimate and forecast revenue of the various products segments end user across the countries of key regions of North America, Europe, APAC and rest of the world regions. Courtiers considered in North America region include USA, Canada, and Mexico. Whereas, Europe covers Germany, Italy, Spain, France, UK and Rest of Europe (RoE). Major countries covered in Asia Pacific include Japan, India, China and Rest of the Asia Pacific. North America accounted for the largest share of the Defibrillators Market in 2018 followed by Europe and Asia Pacific. The large share in the North American region is mainly attributed to the rising incidence of target diseases in the region, technological advancements in defibrillators, and increasing number of public defibrillation programs in the region. Whereas, rapidly growing aging population, improving healthcare infrastructure, and increasing cases of cardiovascular diseases in Asia Pacific region are driving the growth of the Asia Pacific market.
April 2019: Stryker has launched the company's newest defibrillation solution, the LIFEPAK CR2 defibrillator with LIFELINKcentral AED program manager, in the United States. The company has announced that the LIFEPAK CR2 automated external defibrillator (AED) has received Premarket Approval (PMA) by FDA. The LIFPAK CR2 AED was previously released in Europe and Canada in 2017, and in Japan in 2018.
June 2018: Royal Philips announced that it will be providing Philips HeartStart Onsite automated external defibrillators (AEDs) to Vail and Beaver Creek Mountains to create a cardiac arrest response system in collaboration with Starting Hearts and medic assist.
January 2017: Abbott completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The transaction provides Abbott with expanded opportunities for future growth.
Some of the major players operating in this market includes Medtronic, St. Jude Medical LLC, Boston Scientific Corporation, LivaNova, Koninklijke Philips N.V., ZOLL Medical Corporation, Cardiac Science, Physio-Control Inc., Nihon Kohden Corporation, Defibtech LLC, HeartSine Technologies LLC, Progetti Srl, Stryker, Fukuda Denshi Co., Ltd., and Schiller AG among others. Key strategies adopted by most of the key industry players include new product launch, mergers, acquisitions, and business expansion to strengthen product portfolio and maintain their market position.
The report analyses the defibrillators market based on product, end user and geography. The defibrillators are available as implantable cardioverter defibrillators (ICD) and external defibrillators. Implantable cardioverter defibrillators consists of transvenous implantable cardioverter defibrillators and subcutaneous implantable cardioverter defibrillators. transvenous implantable cardioverter defibrillators are accessible as biventricular icds/cardiac resynchronization therapy defibrillators, dual-chamber ICDS, single-chamber ICDS. External defibrillators consists of automated external defibrillators, manual external defibrillators and wearable cardioverter defibrillators. The major end users of the defibrillators are hospitals, clinics, and cardiac centers, pre-hospital care settings, public access markets, alternate care facilities, and home care settings. The global study conducted defibrillators vertical to estimate and forecast revenue of the various products segments end user across the countries of key regions of North America, Europe, APAC and rest of the world regions. Courtiers considered in North America region include USA, Canada, and Mexico. Whereas, Europe covers Germany, Italy, Spain, France, UK and Rest of Europe (RoE). Major countries covered in Asia Pacific include Japan, India, China and Rest of the Asia Pacific.
Some of the major players operating in this market includes Medtronic, St. Jude Medical LLC, Boston Scientific Corporation, LivaNova, Koninklijke Philips N.V., ZOLL Medical Corporation, Cardiac Science, Physio-Control Inc., Nihon Kohden Corporation, Defibtech LLC, HeartSine Technologies LLC, Progetti Srl, Fukuda Denshi Co., Ltd., and Schiller AG among others.
Why to buy this report:
